Value Based Pricing – a Position Statement
Value Based Pricing (VBP) was proposed by Government in 2010 as a key way to deliver improved access to medicines. But detail is lacking, even though confidential Department of Health (DH) and The Association of the British Pharmaceutical Industry (ABPI) negotiations have recently commenced.
This is a critically important moment with respect to research and drug development in the UK. It is vital that the DH and the ABPI (principal negotiators) hear the voice of the rare and less common cancer community now.
Cancer 52, the alliance of more than 60 charities including AMMF, who represent the rare and less common cancers, has put together a Position Statement on Value Based Pricing expressing the concern that VBP could lead to delays in the launch of new treatments or even no launch at all; VBP could blunt incentives for clinical research in the UK and VBP could simply leave those with rare and less common cancers behind.
To read the Position Statement in full, click here:
15 November 2012